Sanofi (SNY) Depreciation & Amortization (CF) (2009 - 2025)

Sanofi (SNY) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $367.1 million in Q1 2025.

• Quarterly Depreciation & Amortization (CF) rose 3.03% year-over-year to $367.1 million in Q1 2025, while the trailing twelve-month figure through Mar 2026 was $0.0 (down 100.0% YoY) and the FY2024 annual result came in at $1.2 billion, down 3.51% from the prior year.
• Depreciation & Amortization (CF) fell to $367.1 million in Q1 2025 per SNY's latest filing, from $1.7 billion in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.7 billion in Q4 2021, with the low at $356.3 million in Q1 2024.
• Average Depreciation & Amortization (CF) over 5 years is $946.6 million, with a median of $418.6 million recorded in 2021.
• Year-over-year, Depreciation & Amortization (CF) gained 3.31% in 2021 and decreased 10.28% in 2024.
• Sanofi's Depreciation & Amortization (CF) stood at $1.7 billion in 2021, then retreated by 3.65% to $1.6 billion in 2022, then advanced by 0.28% to $1.6 billion in 2023, then advanced by 1.75% to $1.7 billion in 2024, then plunged by 77.78% to $367.1 million in 2025.
• Business Quant data shows SNY's Depreciation & Amortization (CF) at $367.1 million in Q1 2025, $1.7 billion in Q4 2024, and $356.3 million in Q1 2024.